Quanome Technologies Reports 111.8% Revenue Growth but Incurred $10.14 Million Net Loss in 2026

Quanome Technologies, Inc. (formerly Lakeside Holding Limited) reported significant financial developments in its recent 10-K filing for the fiscal year ending June 30, 2026. The company generated revenue of $5.85 million, a substantial increase of 111.8% compared to $2.76 million in the previous fiscal year. This growth was primarily driven by higher sales of infusion products and an increase in the number of active customers from eight to twelve. However, the company also reported a net loss of approximately $10.14 million, up from a loss of $1.90 million in the prior year, largely due to increased operating expenses, including a $2.86 million write-off of a supplier advance and a $2.26 million provision for expected credit losses on loans.

In a strategic shift, Quanome completed the disposal of its logistics subsidiary, American Bear Logistics Corp. (ABL Chicago), on February 12, 2026. This move allowed the company to focus on its core pharmaceutical distribution operations through Hupan Pharmaceutical, which accounted for the majority of its revenue. The sale resulted in a gain of $2.56 million, which contributed positively to the financial results for the year. The company is also exploring opportunities in artificial intelligence and quantum-related technologies through its subsidiary, Quantum Nexus, although these initiatives have not yet generated revenue.

Operationally, the company reported a total of 63 customers for its pharmaceutical distribution business, with four customers accounting for over 10% of total revenue each. The company’s gross profit margin improved slightly to 56.7% from 56.1% in the previous year, attributed to better supplier incentives. However, selling expenses surged to $2.64 million from $0.39 million, reflecting increased marketing efforts and the expansion of the sales team. General and administrative expenses also rose significantly, primarily due to professional fees associated with strategic planning initiatives.

As of June 30, 2026, Quanome's total current assets were approximately $11.02 million, with current liabilities of $4.49 million, resulting in a working capital surplus of $6.53 million. The company had a cash balance of $0.67 million, down from $4.81 million the previous year. The liquidity position is notably influenced by a significant loan receivable from a third party, which constitutes a large portion of current assets. The company is actively monitoring this receivable, as any default could adversely impact its liquidity.

Looking ahead, Quanome Technologies is focused on expanding its pharmaceutical distribution business while exploring new ventures in AI and quantum technologies. The company acknowledges the challenges posed by regulatory environments in China and the competitive landscape of the pharmaceutical industry. Management remains committed to securing additional funding and implementing strategic initiatives to enhance growth and operational efficiency.